Skip to content
HomeLatest newsInnovationAbout the Johnson & Johnson Women in STEM²D Scholars Award Program

About the Johnson & Johnson Women in STEM²D Scholars Award Program

WiSTEM microscope

The Johnson & Johnson Scholars Award Program aims to fuel the development of female STEM2D leaders and feed the STEM2D talent pipeline by awarding and sponsoring women at critical points in their research careers, in each of the STEM2D disciplines: Science, Technology, Engineering, Math, Manufacturing and Design.

The awards will fund one woman per discipline who has completed her advanced degree, who is working as an assistant professor or global equivalent and who is not yet tenured at an accredited university or design institution. The goal is to fuel the research passion of the awarded women and inspire career paths in their respective STEM2D fields.

By offering these awards, Johnson & Johnson hopes to play an influential role in STEM2D breakthroughs in the future.

WiSTEM2D Scholars Award

The Johnson & Johnson WiSTEM²D Scholars Award Program will help develop female leaders and support innovation in STEM fields.

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.